1. Safety of Polysorbate 80 in the Oncology Setting
   Lee S. Schwartzberg et al, 2018, Advances in Therapy CrossRef
2. Efficacy of intravenous NEPA, a fixed NK1/5-HT3 receptor antagonist combination, for the prevention of chemotherapy-induced nausea and vomiting (CINV) during cisplatin- and anthracycline cyclophosphamide (AC)-based chemotherapy: A review of phase 3 studies
   Matti Aapro et al, 2021, Critical Reviews in Oncology/Hematology CrossRef
3. Fosnetupitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Short Review and Clinical Perspective
   Masakazu Abe et al, 2023, Advances in Therapy CrossRef
4. Addition of 3-day aprepitant to ondansetron and dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting among patients with diffuse large B cell lymphoma receiving 5-day cisplatin-based chemotherapy
   Raafat Abdel-Malek et al, 2017, Journal of the Egyptian National Cancer Institute CrossRef
5. Safety profile of HTX-019 administered as an intravenous push in cancer patients: a retrospective review
   Rudolph M Navari, 2020, Expert Opinion on Drug Safety CrossRef
6. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE
   Akito Hata et al, 2022, Journal of Clinical Oncology CrossRef
7. Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects
   Tom Ottoboni et al, 2018, Future Oncology CrossRef
8. Extravasation associated with cancer drug therapy: multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical Oncology
   K. Matsumoto et al, 2024, ESMO Open CrossRef
9. Aprepitant and fosaprepitant drug interactions: a systematic review
   Priya Patel et al, 2017, British Journal of Clinical Pharmacology CrossRef
10. Study on the infusion‑site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant
    Miho Yamasaki et al, 2019, Molecular and Clinical Oncology CrossRef
11. Safety assessment of neurokinin-1 receptor antagonist: real-world adverse event analysis from the FAERS database
    Chuanli Yang et al, 2024, Frontiers in Pharmacology CrossRef
12. HTX-019: Polysorbate 80- And Synthetic Surfactant-Free Neurokinin 1 Receptor Antagonist for Chemotherapy-Induced Nausea and Vomiting Prophylaxis
    Rudolph M Navari, 2019, Future Oncology CrossRef
13. Safety Profile of HTX-019 Administered as an Intravenous Push in Cancer Patients: A Retrospective Review
    Gary D. Walton, 2019, Advances in Therapy CrossRef
14. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy
    Lee Schwartzberg et al, 2020, The Oncologist CrossRef
15. A phase 3 safety study of fosnetupitant as an antiemetic in patients receiving anthracycline and cyclophosphamide: CONSOLE‐BC
    Kazuo Matsuura et al, 2022, Cancer CrossRef